Endothelin A Receptor Antagonists

Compounds and drugs that bind to and inhibit or block the activation of ENDOTHELIN A RECECPTORS.

Also Known As:

Antagonists, Endothelin A Receptor; Blockers, Endothelin A Receptor; Endothelin A Receptor Blockers; Endothelin Type A Receptor Antagonists

Networked: 25 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Molecular Mechanisms of Pharmacological Action: 24
    - Endothelin Receptor Antagonists: 1189
      - Endothelin A Receptor Antagonists: 25

Experts

1.	Association of British Clinical Diabetologists and The Renal Association: 1 article (01/2022)
2.	Bain, S: 1 article (01/2022)
3.	Banerjee, D: 1 article (01/2022)
4.	Chowdhury, T A: 1 article (01/2022)
5.	Dasgupta, I: 1 article (01/2022)
6.	De, P: 1 article (01/2022)
7.	Fogarty, D: 1 article (01/2022)
8.	Frankel, A H: 1 article (01/2022)
9.	Karalliedde, J: 1 article (01/2022)
10.	Mark, P B: 1 article (01/2022)

Related Diseases

1.	Proteinuria 09/01/2010 - "Selective endothelin A receptor antagonists have been examined in clinical trials for the treatment of hypertension and proteinuric kidney disease, and appear to be effective in reducing blood pressure and improving proteinuria. "
2.	Kidney Diseases (Kidney Disease) 09/01/2010 - "Selective endothelin A receptor antagonists have been examined in clinical trials for the treatment of hypertension and proteinuric kidney disease, and appear to be effective in reducing blood pressure and improving proteinuria. "
3.	Hypertension (High Blood Pressure) 09/01/2010 - "Selective endothelin A receptor antagonists have been examined in clinical trials for the treatment of hypertension and proteinuric kidney disease, and appear to be effective in reducing blood pressure and improving proteinuria. "
4.	Cardiovascular Diseases (Cardiovascular Disease) 01/01/2019 - "Selective ETA (endothelin-A) receptor antagonists reduce cardiovascular disease risk factors. " 01/01/2022 - "Emerging therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors, non-steroidal selective mineralocorticoid antagonists and endothelin-A receptor antagonists have been shown in randomised trials to lower blood pressure and further reduce the risk of progression of CKD and cardiovascular disease in people with type 2 diabetes. "
5.	Type 2 Diabetes Mellitus (MODY) 01/01/2022 - "Emerging therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors, non-steroidal selective mineralocorticoid antagonists and endothelin-A receptor antagonists have been shown in randomised trials to lower blood pressure and further reduce the risk of progression of CKD and cardiovascular disease in people with type 2 diabetes. "

Related Drugs and Biologics

1.	Sodium
2.	Glucose (Dextrose)
3.	Mineralocorticoid Receptor Antagonists
4.	Atrasentan
5.	Angiotensin II
6.	Phosphodiesterase 5 Inhibitors
7.	Endothelin-1 (Endothelin 1)
8.	Adrenergic Agents (Adrenergic Drugs)
9.	Biomarkers (Surrogate Marker)
10.	Sympathomimetics (Sympathomimetic Amines)

Related Therapies and Procedures

1.	Therapeutics
2.	Heart Transplantation (Grafting, Heart)
3.	Stents